Marissa J. Perman-Laskin, MD
Associate Professor of Clinical Pediatrics (General Pediatrics)
Attending Physician, Hospital of the University of Pennsylvania,
Neonatology
Attending Physician, Children's Hospital of Philadelphia
Clinic Director, Section of Dermatology, Children's Hospital of Philadelphia
Director, Epidermolysis Bullosa Multidisciplinary Clinic, Children's Hospital of Philadelphia
Section Chief, Section of Dermatology, Children's Hospital of Philadelphia
Phototherapy Director, Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
3500 Civic Center Boulevard
Dermatology Section
Philadelphia, PA 19104
3500 Civic Center Boulevard
Dermatology Section
Philadelphia, PA 19104
Office: 215-590-2169
Fax: 215-590-4948
Fax: 215-590-4948
Education:
BA (Near Eastern Studies)
Cornell University, 1999.
MD
University of Maryland School of Medicine, 2005.
Permanent linkBA (Near Eastern Studies)
Cornell University, 1999.
MD
University of Maryland School of Medicine, 2005.
Description of Clinical Expertise
Sunscreen SafetyEpidermolysis Bullosa
Hemangiomas
Atopic Dermatitis
Acne Vulgaris
PCOS
Sports Dermatology
Description of Research Expertise
Epidermolysis bullosaSelected Publications
Shane Swink, DO, Supra Rastogi, MD, Marissa Perman, MD: A Pair of Systematized Linear Porokeratoses Treated with Topical Cholesterol/Lovastatin. Society for Pediatric Dermatology Annual Meeting, Asheville, NC July 2023 Notes: Poster (Cases of the Year).Hannah E. Myers, BS and Marissa Perman, MD: Junctional Epidermolysis Bulls due to LAMB3 Mutations in Skin of Color. Society for Pediatric Dermatology Annual Meeting, Asheville, NC July 2023 Notes: Poster (Cases of the Year).
Charles Y. Hang, Marissa J. Perman, MD, Albert C. Yan, MD: Regimen for Accelerated Propranolol Initial Dosing (RAPID). Society for Pediatric Dermatology Annual Meeting, Asheville, NC July 2023 Notes: Poster (Cases of the Year).
Larijani M, Zarowin D, Wohlschlaeger A, Perman MJ, Treat JR.: Atopic dermatitis-like graft-versus-host disease treated with dupilumab. Pediatr Dermatol 40(2): 320-322, Mar 2023.
Rangu S, Collins J, García-Romero MT, Augsburger BD, Bruckner AL, Diaz LZ, Eichenfield LF, Faig W, Gorell ES, Lefferdink R, Lucky AW, Morel KD, Paller AS, Park H, Pastrana-Arellano E, Peoples K, Wiss K, Perman MJ, Castelo-Soccio L.: Assessing pain catastrophizing and functional disability in pediatric epidermolysis bullosa patients. Pediatr Dermatol 40(3): 422-427, Dec 2022.
Fahad Ahmed, BA, Michael Fisher, MD, Kristen Snyder, MD, Katherine Smith, MPH, BSN, RN, Marissa J. Perman, MD: "Characterizing the Cutaneous Side Effect Profile in Pediatric Patients Receiving MAP Kinase Inhibitor Therapy" PeDRA 2022 Annual Meeting November 2022 Notes: Poster.
Havele SA, Khurana MC, McMahon P, Murthy AS, Perman MJ, Treat JR.: Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis. Pediatr Dermatol 39(2): 291-294, Mar 2022.
Ahmed F, Young LR, Perman MJ.: Junctional epidermolysis bullosa with extensive lung involvement in three patients with a LAMB3 Mutation. Pediatr Dermatol 39(2): 264-267, Mar 2022.
Havele SA, Clark AK, Oboite M, Conrad MA, Perman MJ, Rubin AI, Treat JR.: Bowel-associated dermatosis-arthritis syndrome in a child with very early onset inflammatory bowel disease. Pediatr Dermatol 38(3): 697-698, May 2021.
Robert J. Smith, MD; Michele Khurana, MD; Adam I. Rubin, MD; Bassil Kublaoui, MD; Marissa J. Perman, MD; Aditi S. Murthy, MD : Painful nodules on the abdomen of a teenage male. Pediatric Dermatol 38(5): e12-e13, Apr 2021.